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Background: The brain reward circuitry innervated by dopamine is critically disturbed in
schizophrenia. This study aims to investigate the role of dopamine-related brain activity during
prediction of monetary reward and loss in ﬁrst episode schizophrenia patients.
Methods: We measured blood–oxygen-level dependent (BOLD) activity in 10 patients with
schizophrenia (SCH) and 12 healthy controls during dopamine depletion with α-methylparatyrosine
(AMPT) and during a placebo condition (PLA).
Results: AMPTreduced the activation of striatal and cortical brain regions in SCH. In SCH vs. controls
reduced activation was found in the AMPT condition in several regions during anticipation of reward
and loss, including areas of the striatum and frontal cortex. In SCH vs. controls reduced activation of
the superior temporal gyrus and posterior cingulate was observed in PLA during anticipation of
rewarding stimuli. PLA patients had reduced activation in the ventral striatum, frontal and cingulate
cortex in anticipation of loss. The ﬁndings of reduced dopamine-related brain activity during AMPTElsevier B.V. and ECNP. All rights reserved.
o.2013.06.008
Psychiatry and Psychology, School for Mental Health and Neuroscience, Maastricht University, Postbox
ands. Tel.: +31 433883584.
mc.nl (F. da Silva Alves), t.vanamelsvoort@maastrichtuniversity.nl (T. van Amelsvoort).
F. da Silva Alves et al.1578were veriﬁed by reduced levels of dopamine in urine, homovanillic-acid in plasma and increased
prolactin levels.
Conclusions: Our results indicate that dopamine depletion affects functioning of the cortico-striatal
reward circuitry in SCH. The ﬁndings also suggest that neuronal functions associated with dopamine
neurotransmission and attribution of salience to reward predicting stimuli are altered in schizo-
phrenia.
& 2013 Elsevier B.V. and ECNP. All rights reserved.1. Introduction
Schizophrenia is a serious mental disorder with onset clinical
symptoms typically emerging during adolescence. The esti-
mated lifetime prevalence is approximately 0.3–0.7% and
genetic and environmental factors play a role in the aetiology
of schizophrenia (van Os and Kapur, 2009). Positive (delu-
sions, hallucinations, thought disorganization) and negative
(affective ﬂattening, social withdrawal, anhedonia, lack of
motivation) symptoms of schizophrenia have been attributed
to disrupted dopaminergic neurotransmission and dysfunction
of the brain reward circuitry.
Reward processing is mediated by cortical regions, includ-
ing orbitofrontal, medial dorsolateral prefrontal and cingu-
late cortices and subcortical brain areas such as ventral
striatum, amygdala, thalamus and hippocampus in people
exempt from illness (Bjorklund and Dunnett, 2007; Mogenson
et al., 1980). This circuitry is innervated by dopaminergic
neurotransmission via mesolimbic and mesocortical pathways
and is disrupted in patients diagnosed with schizophrenia
(Davis et al., 1991; Heinz and Schlagenhauf, 2010). People
with schizophrenia have problems with incentive motivation,
prediction of reward, difﬁculty with anticipation of future
positive and negative reward outcomes and difﬁculties
learning from them (Gold et al., 2008; Ziauddeen and
Murray, 2010). In particular, enhanced release of dopamine
in the mesolimbic pathway in schizophrenia may lead to
inappropriate motivational signiﬁcance or aberrant salience
to external and internal stimuli (Kapur, 2003). Hence,
investigation of reward-dopamine related impairment in
schizophrenia may provide insight to the neurobiological
mechanisms of reward and motivation in this disorder.
The ventral striatum, an area of the mesolimbic pathway,
receives much attention in studies investigating the brain
reward circuitry. One of the ﬁrst studies that found evidence
for disrupted striatal dopaminergic neurotransmission in schi-
zophrenia used single photon emission computed tomography
and dopamine depletion with alphamethyl-paratyrosine
(AMPT) (Abi-Dargham et al., 2000). This study showed a
greater increase in striatal dopamine D2 receptor radioligand
binding after dopamine depletion in unmedicated schizophre-
nia patients compared with healthy controls. Also, functional
magnetic resonance imaging (fMRI) studies on reward proces-
sing have shown decreased activation of the ventral striatum
in response to monetary reward-predicting stimuli in unmedi-
cated schizophrenia patients. Probably, increased phasic
dopaminergic activity in striatum in patients with schizophre-
nia interferes with salience attribution and functional activa-
tion to reward-predicting stimuli (Heinz and Schlagenhauf,
2010; Juckel et al., 2006a, 2006b).Our previous study in healthy individuals (da Silva Alves
et al., 2011) showed that acute dopaminergic depletion
attenuated activation of the striatum and cingulate cortices
during anticipation of reward and loss – advocating dopamine's
key role. In the present study, we were interested in brain
activation following dopamine depletion in patients with
schizophrenia compared to healthy controls. We employed
fMRI during AMPT and placebo conditions to investigate how
dopamine depletion affects functional response during reward
processing in schizophrenia patients.
Empirical evidence shows high striatal dopamine turn-
over, as seen in unmedicated schizophrenia patients, to be
associated with changes in phasic dopaminergic signalling of
reward stimuli (Juckel et al., 2006b). Top-down modulation
of this signalling by frontal regions, insula, and cingulate
cortex has also been found compromised for both reward
and loss processing in schizophrenia (Cohen et al., 2012).
In medicated patients, second generation antipsychotics,
which block dopaminergic neurotransmission restored stria-
tal brain activation (Juckel et al., 2006a). Therefore, we
expect no differences in functional response in our group of
schizophrenia patients during anticipation of reward and
loss in the placebo condition in comparison healthy control
subjects. Furthermore, we hypothesize that acute dopa-
mine depletion will reduce activation in frontal regions and
striatum, as these areas have shown to be highly sensitive to
dopaminergic depletion and have been implicated in schizo-
phrenia. Finally, we expect overall brain activation in
schizophrenia to be reduced compared to that of healthy
controls.2. Experimental procedures
2.1. Subjects
A total of 10 male patients with schizophrenia (mean age7SD;
22.7073.2 years) and 12 male healthy controls (34.55711.21
years) were included in the study. Individuals with schizophrenia
(ﬁrst episode patients, duration of illness 1870.8 months) were
recruited from the Adolescent Clinic of the Department of Psychia-
try, Academic Medical Centre, University of Amsterdam (AMC).
Healthy volunteers were recruited by local advertisement. The
study was conducted at the Department of Psychiatry, AMC and was
approved by the local Medical Ethics Committee. All participants
were capable of giving written informed consent and did so, after
receiving full information on the study.
All healthy individuals were interviewed by a physician using
semi-structured psychiatric interview. None of the healthy partici-
pants had a history of psychiatric disorders, medical conditions
affecting brain function, substance or alcohol abuse and they were
not using any medication at the time of testing. Clinical diagnoses
1579Dopaminergic modulation of the reward system in schizophreniaof individuals with idiopathic schizophrenia were made according to
the DSM-IV criteria by two psychiatrists independent of the study.
All patients included met the criteria of the paranoid subtype of
schizophrenia. Patients with schizoaffective psychosis or with
history of drug use were excluded. All patients were receiving care
at the psychiatric open-ward inpatient and day care units of AMC,
and were all medicated at the time of testing. Urine drug screening
(cocaine, tetrahydrocannabinol, opiates, amphetamines, benzodia-
zepines) was performed at the beginning of the ﬁrst and second
study day and was negative in all participating subjects.
The Positive and Negative Symptom Scale (PANSS) (Kay et al.,
1987) was used to assess positive, negative and general psycho-
pathology in the patient group. In addition, for assessment of
intelligence quotient (IQ) we used the shortened Dutch version of
the Wechsler Adult Intelligence Scale (WAIS-III–NL) consisting of ﬁve
subtests: vocabulary, comprehension, similarities (verbal IQ), block
design, and object assembly (performance IQ) (Canavan et al.,
1986; Wechsler, 1997). For demographics and clinical variables see
Table 1.2.2. Study design and dopamine challenge
All subjects underwent two fMRI measurements (Day I and Day II)
with an inter-scan interval of approximately 8 days. The fMRI study
was conducted as a randomized double blind controlled study, with
two conditions: (1) administration of AMPTand (2) administration of
placebo (cellulose, corn starch) tablets. On day 1, baseline samples
of blood and urine were collected and AMPT or placebo was
administered at 8.00 h (T0). Subsequently, AMPT or placebo was
administered again 2 h later at 10.00 h (T2) followed by collection
of blood samples at 11.00 h (T3). At 12.00 h (T4) the last dose of
AMPT or placebo was administrated. The fMRI scanning started 1 h
after the last dose of AMPT at 13.00 h (T5). At the end of the fMRI
session at 14.00 h (T6) the last blood and urine samples were
collected. On day 2 the same procedures were employed, however
this time subjects were assigned to the other treatment condition
(AMPT/placebo) according to the crossover design. To assess the
effects of AMPT on subjective well being we used the ‘subjective
well-being under neuroleptic’ questionnaire (SWN) (de Haan et al.,
2002; Naber, 1995) on both study days.
Three doses of 500 mg AMPTwere orally administered (total dose
1.5 g) over two intervals of 2 h. These doses were similar to
those used by Boot et al. (2008) and da Silva Alves et al. (2011).Table 1 Demographics and clinical variables.
Patients (10) Controls (12)
Age 22.70773.2 34.557711.21
Years of education 10.8 (1.5) 13.7 (2.8)
Handedness 8R/2L 10R/2L
WAIS-III IQ 90.30 (16.24) 96.64 (11.72)
PANSS total 51.58 (9.61)
PANSS positive 12.16 (3.18)
PANSS negative 14.42 (5.57)
Antipsychotic
medication
Clozapine (1)
Risperidone (2)
Olanzapine (1)
Quetiapine (2)
Aripiprazole (3)
Haloperidol (1)Urine samples were collected at T0 and T6 for determining
DA levels. Blood samples were drawn at T0, T3, and T6 for
assessment of plasma levels of prolactin (PRL) and HVA, a catecho-
laminergic metabolite of dopamine. Detailed description of AMPT
administration and assessment of catecholamines, their metabo-
lites and prolactin was as previously explained (da Silva Alves
et al., 2011).
2.3. fMRI task: monetary incentive delay
We used event-related fMRI to assess BOLD brain activation during
the monetary incentive delay (MID) task (Knutson et al., 2001a).
In short, the MID task was used to evoke anticipation of potential
monetary reward, loss, or no consequential outcome. It consists of
two sessions of 72 trials of 6 s, yielding a total of 144 trials and total
duration of 14 min. During each trial, subjects were shown one of
the seven cues. Cues signalling reward were denoted by circles
(n=54), loss by squares (n=54), and no monetary outcome by
triangles (n=36). The amount of money that subjects were able to
win was indicated by one horizontal line (0.20 Euro), two lines (1.00
Euro) and three lines (5.00 Euros). Similarly, loss cues signalled the
possibility of losing the same amounts of money. Subjects had to
respond to the white target square that appeared for a variable
length of time. To succeed in a trial, volunteers had to press the
button during the time that the white square target was visible
(target, 160–260 ms). Unlike the MID described by Knutson et al.
(2001a, 2001b) we were unable to pay the amount of money earned
during the task, reward and loss was based on point scoring.
2.4. fMRI data acquisition
fMRI data were collected using a 3T MRI Philips system equipped with a
sense head coil as previously explained(da Silva Alves et al., 2011). The
task stimuli were generated using the e-prime software (SCOPE V2.5.4/
Pentium). For the MID task 360 event related, transversal multislice T2n-
weighted gradient-echo planar images (EPI) were acquired with: echo
time (TE) 30 ms, repetition time (TR) 2000 ms, 96 96 matrix, 35
slices, 3 3 mm in-plane resolution, slice thickness 3 mm with a 1 mm
interslice gap, covering the entire brain. For anatomical localization
transversal high-resolution structural T1-weighted volumetric images
were acquired in the same session, with full head coverage, using 150
contiguous slices (1 mm thick, with 0.89 0.89 mm2 in-plane resolu-
tion), a 256 256 124 matrix and a TR/TE of 24/5 ms (ﬂip angle 451,
FOV 24 cm).
2.5. fMRI data pre-processing
All functional and structural brain images were pre-processed blind
for design condition as previously explained (da Silva Alves et al.,
2011). Slice time correction was used to adjust for time differences
due to multi-slice image acquisition. After the realignment of the
scans, visual inspection of motion-correction estimates showed that
some subjects had head movements greater than 5 mm. Hence, the
movement artefacts were included as regressors in the further pre-
processing. The pre-processed fMRI data were then analyzed in the
context of the general linear model (GLM) approach (Friston et al.,
1995) using a two-level procedure.
3. Statistical analysis
3.1. Catecholamines, their metabolites and
prolactin
Compiled data are expressed as mean7SD. To check whether
dependent variables were normally distributed visual
F. da Silva Alves et al.1580inspection of histograms and Kolmogorov–Smirnov (Lillifors)
test were applied. In the event of signiﬁcantly skewed
distributions, natural base logarithmic transformations were
applied to allow for parametric statistical procedures.
Between-group comparisons were performed using
independent-sample t-tests. Challenge, time and group main
effects and all interaction effects for the dopaminergic
markers were tested with GLM repeated. A probability value
of 0.05 two-tailed was selected as level of signiﬁcance.
Statistical analyses were performed with SPSS, release 16.0.2
for Windows (SPSS Inc., Chicago, IL, USA, 2008).3.2. fMRI data analysis
The analyses focused on changes in BOLD contrast that
occurred during anticipatory delay periods and were con-
ducted using the SPM8 (http://www.ﬁl.ion.ucl.ac.uk/spm/).
The ﬁrst level data analysis was performed by modelling the
different conditions (reward, loss, no monetary outcome).
Changes in the BOLD response were assessed using the
estimated GLM parameters for the anticipation of potential
monetary gain vs. anticipation of no monetary outcome
(reward vs. no outcome) and the anticipation of potential
monetary loss vs. anticipation of no monetary outcome (loss
vs. no outcome). In the second level analysis, individual
contrast images of the ﬁrst level analysis were included in a
two-sample t-test to detect relevant brain activation in
patients with schizophrenia and in healthy controls during
AMPT and placebo conditions. To account for differences in
age between the groups, age was included as a covariate in
the between group analysis. For the whole brain analysis,
comparisons were corrected for multiple comparisons using
family wise error correction (FWEcor) Po0.05 at cluster level
(extent threshold of 10 voxels). Voxels and clusters were
localized using the MNI coordinates and transformed into
Talairach and Tournoux coordinates (Brett et al., 2002). Next
to the whole brain analyses, we conducted region of interest
(ROI) analyses focusing on activation within the left and right
striatum since these brain regions are implicated in reward
processing (Knutson et al., 2001b) and show pathology in
schizophrenia (Gold et al., 2008; Juckel et al., 2006b). ROIs
were structurally deﬁned a priori which included the whole
striatum. We used the Marsbar toolbox (http://marsbar.sour
ceforge.net) to extract mean parameter estimates averaged
across all voxels in each ROI (FWEcor) Po0.05.4. Results
Schizophrenia patients were younger than healthy controls (HC
34.55711.21, SCZ 22.7073.2; P=0.006) Table 1. There were
no differences between schizophrenia patients and healthy
controls in total IQ (HC 96.64711.72, SCZ 90.30716.24;
P=0.31). Scores on the subscale of the PANSS were positive
12.1673.18, negative 14.4275.57 and general psychopathol-
ogy 25.0075.45. Total of PANSS score was 51.5879.61. The
total SWN score did not differ between the two conditions
(AMPT was 66.4579.8, PLA 66.7079.55; P=0.95). However,
SWN subscale scores indicated that participants experienced
more loss of self control in the AMPT condition than after
placebo condition (AMPT 17.1871.84, PLA 15.5071.78;P=0.05). Four of the healthy controls and four patients were
smokers (last cigarette approximately 90 min before scanning).
4.1. Behavioural effects of dopamine depletion
No serious adverse events like acute dystonia or crystalluria
were observed. Plasma levels of AMPT showed signiﬁcant
increase from T3 to T6 in both, healthy controls (T3
12.12 mg/l73.87; T6 16.75 mg/l74.75, t(10)=2.58,
P=0.03) and schizophrenia patients (T3 14.19 mg/l73.05;
T6 18.69 mg/l72.21, t(9)=3.71, P=0.005). Plasma levels
of AMPTwere not signiﬁcantly different between the groups
(F(1, 19)=3.09, P=0.09).
4.2. Task performance
Healthy control reaction times in reward (PLA 226.9 ms771.72,
AMPT 268.40 ms784.53; t(22)=1.30, P=0.21) and loss (PLA
240.82 ms772.05, AMPT 280.27 ms786.15; t(22)=1.22,
P=0.24) did not differ across challenge conditions. Schizophre-
nia patients were slower in AMPT than in placebo in both
reward (PLA 261.94 ms796.60, AMPT 346.83 ms746.31; t(18)
=2.50, P=0.02) and loss (PLA 276.81 ms776.82, AMPT
359.59 ms719.19; t(18)=3.31, P=0.004).
Repeated measures ANOVA showed a signiﬁcant main
effect of incentive value (F(1, 20)=10.96, Po0.001) and a
signiﬁcant main effect of challenge (F(1, 20)=9.31,
Po0.001) and group (F(1, 20)=5.60, Po0.03). Schizophre-
nia and patients did not differ for anticipation of reward or
loss in the placebo condition. However, in the AMPT
condition patients were slower than healthy controls in
both, the reward condition (t(20)=2.62, P=0.02) and the
loss condition (t(20)=2.84, P=0.01).
4.3. Neuro-endocrine response and peripheral
markers for dopamine
Means and standard deviations for neuro-endocrine (PRL) and
peripheral markers for dopamine (DA, HVA) are displayed in
Table 2. Effects of AMPT on the peripheral markers of
dopamine in schizophrenia patients are shown in Figure 1.
Repeated measures ANOVA for PRL showed a signiﬁcant
main effect of condition (F(1, 14)=20.84, Po0.001) on
plasma PRL and a signiﬁcant interaction of condi-
tion group (F(1, 14)=9.34, P=0.009). In both schizophre-
nia patients and healthy controls levels of plasma PRL
decreased between T0 and T6 in the placebo condition,
whereas in the AMPT condition the prolactin levels showed
an increase between T0 and T6. Schizophrenia patients had
marked higher levels of PRL compared to healthy controls in
the placebo condition. The difference of PRL levels between
placebo and AMPT was larger in healthy controls than in
schizophrenia.
Repeated measures ANOVA for urine DA showed a sig-
niﬁcant effect of condition (F(1, 16)=16.79, Po0.001) and
a signiﬁcant interaction of condition time (F(1, 16)
=47.61, Po0.001). DA levels in urine in both groups
decreased from T0 to T6 in the AMPT condition. Schizo-
phrenia patients had higher levels of DA in urine compared
to healthy controls in both placebo and AMPTcondition. The
Table 2 Neuro-endocrine response and peripheral markers.
Marker Condition Schizophrenia Healthy controls
T0 T3 T6 T0 T3 T6
PRL (mg/l) PLA 35.00731.58 29.53730.95 25.86729.36 11.3975.85 8.3774.08 7.9573.32
AMPT 36.41730.53 45.12735.34 37.21733.50 14.1075.70 42.65720.94 29.30711.32
P=0.87 P=0.42 P=0.66 P=0.14 Po0.001 Po0.001
DA urine
(nmol/mmol
creat)
PLA 156.90751.87 – 162.25746.24 121.107734.80 – 132.907746.98
AMPT 159.56750.69 – 72.89732.03 135.70737.99 – 65.50718.34
P=0.85 P=0.002 P=0.37 Po0.001
HVA plasma
(nmol/l)
PLA 82.46732.38 62.32728.77 59.14725.05 70.73730.84 57.35722.06 47.29713.49
AMPT 91.04748.99 44.32717.04 32.23715.44 72.10741.20 39.37720.07 26.50713.49
P=0.34 P=0.04 P=0.004 Po0.11 P=0.03 P=0.001
T0=8.00 h; T3=11.00 h; T6=14.00 h.
PRL=prolactin; DA=dopamine; HVA=homovanillic acid; NE=norepinephrine.
AMPT=α-methylparatyrosine; PLA=placebo.
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Fig. 1 Effect of AMPT on peripheral markers of dopamine in
schizophrenia patients.
1581Dopaminergic modulation of the reward system in schizophreniadifference of DA in urine between T0 and T6 was larger in
AMPT than in placebo condition.
Repeated measures ANOVA for plasma HVA showed a
signiﬁcant effect of condition (F(1, 15)=22.37, Po0.001)
and a signiﬁcant interaction of condition time (F(2, 14)
=12.54, Po0.001). Levels of plasma HVA decreased over
time and were lower in AMPT than in placebo condition.
Although not signiﬁcant, in both the placebo and AMPT
condition the schizophrenia had higher levels of plasma HVA
at all three time intervals compared to healthy controls.5. fMRI ﬁndings
5.1. Schizophrenia patients
5.1.1. Placebo vs. AMPT condition
During anticipation of reward, schizophrenia patients sig-
niﬁcantly activated the right inferior frontal gyrus, insula
and middle frontal gyrus (Pco0.001, Pc: corrected for
multiple comparisons at cluster level) (Figure 2). In addi-
tion, they activated the medial frontal gyrus bilaterally and
the left anterior cingulate (Pco0.05) (Table 3). During the
anticipation of loss, patients activated the right inferior
frontal gyrus (Pco0.001).
ROI analysis showed signiﬁcant activation of the left
ventral striatum Pco0.001.5.1.2. AMPT vs. placebo condition
Schizophrenia patients showed no signiﬁcant brain activa-
tion during anticipation of reward or anticipation of loss,
anticipation of reward vs. loss or loss vs. reward.
5.1.3. Schizophrenia vs. healthy controls
5.1.3.1. Placebo condition. During anticipation of reward,
schizophrenia patients compared to controls showed
reduced brain activation (Pco0.001) in the right superior
temporal gyrus and left posterior cingulate (Table 4,
Figure 3). During anticipation of loss schizophrenia patients
vs. controls showed reduced activation in several areas of
the brain including the left cingulate gyrus and left ventral
striatum (Pco0.05).
ROI analysis showed reduced activation of the left ventral
striatum (Pco0.001) during anticipation of loss.
5.1.3.2. AMPT condition. During anticipation of reward,
schizophrenia patients compared to controls showed
reduced brain activation in the right inferior and middle
frontal gyrus (Pco0.001). Schizophrenia patients vs. con-
trols showed no signiﬁcant brain activation during anticipa-
tion of loss.
ROI analysis showed reduced activation of the left
(ventral) striatum (caudate head and body) (Pco0.001)
during anticipation of reward and anticipation of loss.
6. Discussion
The current study is the ﬁrst to assess the modulatory role of
dopamine on activation of in the brain reward system in
patients with schizophrenia through an AMPT depletion para-
digm. Our main ﬁndings show that schizophrenia patients had
overall reduced brain activation during anticipation of mone-
tary reward and loss following dopamine depletion. Therefore,
in schizophrenia activation patterns in reward related proces-
sing are directly affected by concentration of dopamine.
Previous studies show aberrant reward and loss
stimuli cueing in schizophrenia and have attributed this
to changes in dopaminergic neurotransmission (Abi-
Dargham, 2004) but none have discerned the modulatory
Fig. 2 Brain activation in schizophrenia patients during anticipation of reward (x=48y=22z=6). AMPT impaired recruitment of
striatal and cortical regions in schizophrenia.
Table 3 Brain regions showing signiﬁcant BOLD activation associated with anticipation of reward and loss in schizophrenia.
Conditions Brain regions BA Talairach coordinates t-Value
X y z
PLA4AMPT 1a. Anticipation of reward4no outcome
Inferior frontal gyrus BA 45 R 48 22 6 7.2
Medial frontal gyrus BA 10 R 32 42 14 6.8
Insula BA 13 R 36 12 0 4
Middle frontal gyrus BA 46 R 44 20 18 4
Anterior cingulate BA 32 L 6 30 20 4.12
1b. Anticipation of loss4no outcome
Inferior frontal gyrus BA 45 R 48 24 8 7.05
Insula BA 47 R 34 16 2 5.59
Lentiform nucleus putamenn L 22 10 10 5.17
AMPT4PLA – – – –
AMPT=α-methylparatyrosine; PLA=placebo; BA=Brodmann area; L= left; R=right.
po0.05 corrected for multiple comparisons at cluster level.
nROI, po0.001 corrected.
F. da Silva Alves et al.1582role of dopamine on activation of critical nodes in the
reward brain circuitry. In the present study reduced
overall brain activation was found during salience proces-
sing of monetary reward and loss cues in the AMPT
condition in schizophrenia. An earlier study conductedby our research group found that dopamine depletion
attenuates activation in the cingulate cortex and ventral
striatum (da Silva Alves et al., 2011) in health subjects. A
similar effect was found in the patients with schizophre-
nia in the present study. These ﬁndings are consistent
Table 4 Brain regions showing signiﬁcant BOLD activation associated with anticipation of reward and loss in schizophrenia
compared to healthy controls.
Conditions Brain regions BA Talairach coordinates t-Value
X y z
HC4SCZ PLACEBO 1a. Anticipation of reward4no outcome
Superior temporal gyrus 41 R 34 30 6 4.65
Posterior cingulate 29 L 2 46 8 3.93
2a. Anticipation of LOSS4no outcome
Inferior frontal gyrus 47 R 38 16 14 5.84
Lentiform nucleus L 16 16 4 4.65
Superior frontal gyrus 6 L 4 16 62 4.3
Cingulate gyrus 32 L 6 26 32 4.64
Medial frontal gyrus 9 L 16 24 26 4.19
Anterior cingulate 24 L 4 24 22 4.01
Lentiform nucleusn L 20 14 6 4.7
HC4SCZAMPT 1b. Anticipation of reward4no outcome
Inferior frontal gyrus 13 R 38 24 12 5.63
Middle frontal gyrus 10 R 32 42 14 4.75
Lentiform nucleusn L 20 12 6 3.83
L 22 10 12
2b. Anticipation of loss4no outcome
Caudate headn L 14 18 8 4.81
Caudate bodyn L 18 16 10 4.63
AMPT=α-methylparatyrosine; PLA=placebo; BA=Brodmann area; L= left; R=right.
po0.05 corrected for multiple comparisons at cluster level.
nROI, po0.001 corrected.
Fig. 3 Areas of reduced brain activation in schizophrenia patients vs. healthy controls during anticipation of reward (x=34y=
30z=6).
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F. da Silva Alves et al.1584with neuroleptic-induced blunting of the brain reward
system (Abler et al., 2007; Menon et al., 2007).
A depletion paradigm in schizophrenia patients allows for
investigation of changes in systemic functional response
inherent to dopamine that are absent in healthy controls,
and thus attributable to illness pathology. Comparisons in
the current study between healthy control subjects and
patients with schizophrenia in AMPT showed reduced func-
tional response of the inferior and middle frontal gyrus, and
ventral striatum during anticipation of reward. During
anticipation of loss of incentive reduced activation was
found in the striatum, including the caudate head and body.
These ﬁndings may suggest higher sensitivity of striato-
cortical reward circuitry to dopamine depletion in schizo-
phrenia. In addition empirical evidence shows functional
domain speciﬁcity of the inferior frontal gyrus and middle
frontal gyrus in mediating signalling of reward and loss. The
inferior frontal gyrus exerts response suppression and plays a
role in modulation of attention (Aron et al., 2003; Carter et al.,
1995). Middle frontal regions mediate integration of internal
and external cues to adjusting response strategies and atten-
tional bias – such as to rewarding event (Ridderinkhof et al.,
2004). Therefore results show these processes to be suscept
to dopamine modulation and pathologically affected in
schizophrenia.
In unmedicated patients with depression AMPT reduced
function of brain reward system and proposed to represent a
trait-like biological marker of major depression (Hasler
et al., 2009). Because our group of schizophrenia patients
was medicated we cannot conclude on the state-trait
effects. Given that dopamine imbalance is a consistent
ﬁnding in schizophrenia we believe that the sensitivity to
dopamine depletion observed in our study may also repre-
sent an inherent aspect of schizophrenia.
In the placebo condition, within group results show activity
concentrated in frontal areas and insular cortex in the brains
of schizophrenia patients during anticipation of reward.
Contrary to expectation patients did not show activation of
the striatum. This is in contrast to other studies which show
normal activation patterns in medicated schizophrenia
patients to monetary reward in the ventral striatum (Juckel
et al., 2006a; Schlagenhauf et al., 2008; Walter et al., 2009).
However, Cohen et al. (2012) established that during reward
anticipation there is frontal top-down directed EEG syn-
chrony to the ventral striatum. Activation of these regions
in placebo condition was found in schizophrenia in the
current study, yet this activation was hypoactive in compar-
ison to healthy control subjects. Therefore failure to ﬁnd
signiﬁcant activation of the ventral striatum may be the
result of changes in top-down innervations of frontal regions.
During anticipation of loss signiﬁcant activation in the
ventral striatum was found in placebo compared to AMPT
condition. Between group comparisons show schizophrenia
patients compared to controls had reduced activation in
ventral striatum and more anterior areas, including frontal
and cingulate cortex, during anticipation of loss. Therefore,
results indicate that dopaminergic neurotransmission in
subcortical regions of the brain reward system may have
not been normalized by medication in our group of schizo-
phrenia patients. Results also indicate that in as early as
ﬁrst episode schizophrenia patients changes in systemic
functional response to dopaminergic neurotransmissionseem to have manifested. A recent study has not detected
these differences in activation in reward and loss cueing in
prodromal patients (Juckel et al., 2012). Research of this
nature is highly relevant in better understanding effects of
antipsychotics vs. illness pathology.
Abnormal activity of the ventral striatum during reward
processing in schizophrenia was proposed to be a characteristic
of a subset of medicated schizophrenia patients with high
negative symptoms (Simon et al., 2010; Waltz et al., 2010). This
was probably not the case in our group of patients. The
schizophrenia patients had low scores on the three subscales
of the PANSS conﬁrming remission of symptoms. It seems that
antipsychotic medication stabilized the symptoms but we could
not detect this normalizing effect in brain activity. It is
important to note that the patients in this study were ﬁrst
episode psychotic patients in the initial phase of antipsychotic
treatment, mostly with atypical antipsychotics that reach their
therapeutic effect by blocking striatal dopamine D2 receptors,
perhaps disallowing activation to reach statistical signiﬁcance.
This is the ﬁrst study to investigate the effects of dopamine
depletion in the reward system of schizophrenia patients. The
randomized double blind placebo approach and the compar-
ison with healthy individuals is a major strength of this study.
Moreover, extent of dopamine depletion was assessed by
peripheral dopamine markers conﬁrming the effect of AMPT
in both groups. Additional veriﬁcation of the effect AMPTwas
found in impaired performance on the reward task in the
schizophrenia group.
Several limitations of this study need to be addressed in
future research. First, the patients were treated with various
types and dosages of atypical antipsychotic medication which
may have some differential effect on the dopamine function
and metabolism (Bressan et al., 2003; Seeman, 2002).
However, inferences of functional differences as a function
of dopamine can still be made. The therapeutic window of
antipsychotic medication lies at 65–80% blockade at D2
(Uchida et al., 2011), rendering a maximum of 20–35% of
D2 receptors free to bind with endogenous dopamine. There-
fore, although the patients were on treatment with anti-
psychotics, we could still access the functional effects of the
dopamine depletion. The dopamine depletion design with
AMPT allows us to assess overall endogenous dopamine
function and reﬂects pre-synaptic dopaminergic function,
whereas antipsychotic medication reﬂects post-synaptic
dopaminergic function through D2 receptor blockade.
Future research must also address the potential effect of
age on functional response of the brain circuitry. In the
current study the patient group was younger than the
healthy controls. Aging is associated with changes in
maturation of the mesolimbic circuitry probably altering
dopaminergic signals (Backman et al., 2006) and striatal
activation was shown to vary with age (Bjork et al., 2004;
Samanez-Larkin et al., 2007; Schott et al., 2007). The latter
study reported intact striatal activation to reward in old age
and a relative reduction during loss anticipation (Samanez-
Larkin et al., 2007). Although we have co-varied for age,
implications of age for reward brain function further studies
are necessary to address this issue.
Another aspect to take into consideration is the explorative
nature of the present study with a relatively small sample
size. However, the number of subjects was sufﬁcient for a
power of 80% and alpha of 0.002 (Desmond and Glover, 2002).
1585Dopaminergic modulation of the reward system in schizophreniaEarlier fMRI studies of the reward system have found results
sustaining the proposed expectations with similar or smaller
sample sizes (Knutson et al., 2001a, 2004). The subjects in our
study did not earn the actual amount of money presented
during the MID task. The task was based in point scoring which
is commonly used to investigate functional activation of the
reward system. However, we cannot discharge the possibility
that this could have resulted in lower drive to accomplish the
best performance and consequently having a differential
effect on striatal activation. Furthermore our study only
measures the BOLD response, which rather indirectly reﬂects
brain activation, and does not directly address dopaminergic
neurotransmission.
This study provides insight in the impairment of
dopamine-related reward system in schizophrenia. We
found overall reduced brain activation during anticipation
of monetary reward and loss after dopamine depletion in
medicated schizophrenia patients. We show that this system
in schizophrenia is sensitive to dopamine depletion during
reward predicting stimuli. We observed a clear imbalance of
dopamine-related brain activity in the early phase of
antipsychotic treatment. Neurobiological mechanisms of
reward in schizophrenia involve a complex dopaminergic
loop including, next to striatal regions, also frontal brain
regions. Future studies that combine fMRI with other brain
imaging techniques measuring the degree of dopamine
depletion may help to further understand the therapeutic
effects and resistance to antipsychotic drugs.Role of funding source
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